Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 56. More products

ENALAPRIL MALEATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Apo-Enalapril · DIN 02020025 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Enalapril · DIN 02020025 Manufacturer: Apotex Inc.; listing date 2007-12-19 Daily cost (source): $0.1863 Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14385 · Verify on the e-Formulary ↗ (DIN 02020025)

Source record
DIN 02020025: Apo-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02020025 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14385
Interchangeable products
Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2021-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02020025
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Co Enalapril · DIN 02291878 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Enalapril · DIN 02291878 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19 Daily cost (source): $0.1863 Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 2 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77724 · Verify on the e-Formulary ↗ (DIN 02291878)

Source record
DIN 02291878: Co Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id COB Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291878 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77724 Therapeutic Notes (formulary) ** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2025-02-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291878
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02400650 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Enalapril · DIN 02400650 Manufacturer: Sanis Health Inc.; listing date 2022-02-28 Daily cost (source): $0.1863 Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88543 · Verify on the e-Formulary ↗ (DIN 02400650)

Source record
DIN 02400650: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400650 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88543
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2022-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400650
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02442957 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Enalapril · DIN 02442957 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Daily cost (source): $0.1863 Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 2 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92748 · Verify on the e-Formulary ↗ (DIN 02442957)

Source record
DIN 02442957: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442957 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92748
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2020-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442957
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Enalapril · DIN 02474786 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Enalapril · DIN 02474786 Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30 Daily cost (source): $0.1863 Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96497 · Verify on the e-Formulary ↗ (DIN 02474786)

Source record
DIN 02474786: Jamp-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474786 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96497
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2024-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474786
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Enalapril · DIN 02459450 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Enalapril · DIN 02459450 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28 Daily cost (source): $0.1863 Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94669 · Verify on the e-Formulary ↗ (DIN 02459450)

Source record
DIN 02459450: Mar-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459450 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94669
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ran-Enalapril · DIN 02352230 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459450
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Enalapril · DIN 02352230 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Enalapril · DIN 02352230 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07 Daily cost (source): $0.1863 Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 2 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Enalapril: Formulary list price $0.1863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83747 · Verify on the e-Formulary ↗ (DIN 02352230)

Source record
DIN 02352230: Ran-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id RAN Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1863; ministry $0.1863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352230 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83747
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863 Co Enalapril · DIN 02291878 · $0.1863 Enalapril · DIN 02400650 · $0.1863 Enalapril · DIN 02442957 · $0.1863 Jamp-Enalapril · DIN 02474786 · $0.1863 Mar-Enalapril · DIN 02459450 · $0.1863 Mylan-Enalapril · DIN 02300036 · $0.1863 Novo-Enalapril · DIN 02300680 · $0.1863 Ratio-Enalapril · DIN 02299984 · $0.1863 Sandoz Enalapril · DIN 02299933 · $0.1863 Taro-Enalapril · DIN 02300117 · $0.1863 Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended 2025-04-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352230
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Enalapril · DIN 02019884 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Enalapril · DIN 02019884 Manufacturer: Apotex Inc.; listing date 2007-12-19 Daily cost (source): $0.2203 Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14386 · Verify on the e-Formulary ↗ (DIN 02019884)

Source record
DIN 02019884: Apo-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019884 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14386
Interchangeable products
Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended 2024-11-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019884
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Co Enalapril · DIN 02291886 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Enalapril · DIN 02291886 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19 Daily cost (source): $0.2203 Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77725 · Verify on the e-Formulary ↗ (DIN 02291886)

Source record
DIN 02291886: Co Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id COB Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291886 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77725 Therapeutic Notes (formulary) ** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291886
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02400669 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Enalapril · DIN 02400669 Manufacturer: Sanis Health Inc.; listing date 2022-02-28 Daily cost (source): $0.2203 Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88544 · Verify on the e-Formulary ↗ (DIN 02400669)

Source record
DIN 02400669: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400669 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88544
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended 2022-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400669
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02442965 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Enalapril · DIN 02442965 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Daily cost (source): $0.2203 Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92749 · Verify on the e-Formulary ↗ (DIN 02442965)

Source record
DIN 02442965: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442965 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92749
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended 2018-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442965
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Enalapril · DIN 02474794 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Enalapril · DIN 02474794 Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30 Daily cost (source): $0.2203 Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96498 · Verify on the e-Formulary ↗ (DIN 02474794)

Source record
DIN 02474794: Jamp-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474794 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96498
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended 2024-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474794
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Enalapril · DIN 02459469 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Enalapril · DIN 02459469 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28 Daily cost (source): $0.2203 Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94670 · Verify on the e-Formulary ↗ (DIN 02459469)

Source record
DIN 02459469: Mar-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id MAR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459469 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94670
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459469
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Enalapril · DIN 02352249 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Enalapril · DIN 02352249 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07 Daily cost (source): $0.2203 Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 4 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Enalapril: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83748 · Verify on the e-Formulary ↗ (DIN 02352249)

Source record
DIN 02352249: Ran-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id RAN Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352249 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83748
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203 Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended 2025-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352249
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Vasotec · DIN 00708879 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Vasotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Vasotec · DIN 00708879 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.2182 Health Canada: Marketed since 2022-04-11 · brand VASOTEC · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8111 · Verify on the e-Formulary ↗ (DIN 00708879)

Source record
DIN 00708879: Vasotec Raw flags: chronicUseMed=Y, sec3=Y Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id OCI Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.2182; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00708879 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8111 Therapeutic Notes (formulary) ** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203 Co Enalapril · DIN 02291886 · $0.2203 Enalapril · DIN 02400669 · $0.2203 Enalapril · DIN 02442965 · $0.2203 Jamp-Enalapril · DIN 02474794 · $0.2203 Mar-Enalapril · DIN 02459469 · $0.2203 Mylan-Enalapril · DIN 02300044 · $0.2203 Ran-Enalapril · DIN 02352249 · $0.2203 Ratio-Enalapril · DIN 02299992 · $0.2203 Sandoz Enalapril · DIN 02299941 · $0.2203 Taro-Enalapril · DIN 02300125 · $0.2203 Teva-Enalapril · DIN 02233005 · $0.2203
Shortage status: active shortage (reported 2026-06-25, estimated to end 2026-10-09, last updated 2026-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00708879
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Enalapril · DIN 02019892 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Enalapril · DIN 02019892 Manufacturer: Apotex Inc.; listing date 2007-12-19 Daily cost (source): $0.2647 Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14387 · Verify on the e-Formulary ↗ (DIN 02019892)

Source record
DIN 02019892: Apo-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019892 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14387
Interchangeable products
Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended 2022-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019892
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Co Enalapril · DIN 02291894 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Enalapril · DIN 02291894 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19 Daily cost (source): $0.2647 Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77726 · Verify on the e-Formulary ↗ (DIN 02291894)

Source record
DIN 02291894: Co Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id COB Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291894 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77726 Therapeutic Notes (formulary) ** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291894
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02400677 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Enalapril · DIN 02400677 Manufacturer: Sanis Health Inc.; listing date 2022-02-28 Daily cost (source): $0.2647 Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88545 · Verify on the e-Formulary ↗ (DIN 02400677)

Source record
DIN 02400677: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400677 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88545
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended 2022-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400677
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enalapril · DIN 02442973 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Enalapril · DIN 02442973 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Daily cost (source): $0.2647 Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92750 · Verify on the e-Formulary ↗ (DIN 02442973)

Source record
DIN 02442973: Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442973 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92750
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended 2018-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442973
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Enalapril · DIN 02474808 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Enalapril · DIN 02474808 Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30 Daily cost (source): $0.2647 Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96499 · Verify on the e-Formulary ↗ (DIN 02474808)

Source record
DIN 02474808: Jamp-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474808 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96499
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended 2024-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474808
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Enalapril · DIN 02444771 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Enalapril · DIN 02444771 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28 Daily cost (source): $0.2647 Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92998 · Verify on the e-Formulary ↗ (DIN 02444771)

Source record
DIN 02444771: Mar-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02444771 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92998
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02444771
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Enalapril · DIN 02352257 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Enalapril · DIN 02352257 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07 Daily cost (source): $0.2647 Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 8 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Enalapril: Formulary list price $0.2647/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83749 · Verify on the e-Formulary ↗ (DIN 02352257)

Source record
DIN 02352257: Ran-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id RAN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352257 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83749
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended 2023-11-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352257
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Vasotec · DIN 00670901 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Vasotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Vasotec · DIN 00670901 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.4638 Health Canada: Marketed since 2022-04-07 · brand VASOTEC · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8102 · Verify on the e-Formulary ↗ (DIN 00670901)

Source record
DIN 00670901: Vasotec Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id OCI Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4638; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00670901 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8102 Therapeutic Notes (formulary) ** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647 Co Enalapril · DIN 02291894 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647
Shortage status: resolved shortage (ended 2024-09-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00670901
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Enalapril · DIN 02019906 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Enalapril · DIN 02019906 Manufacturer: Apotex Inc.; listing date 2007-12-19 Daily cost (source): $0.3195 Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Enalapril: Formulary list price $0.3195/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3195 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14388 · Verify on the e-Formulary ↗ (DIN 02019906)

Source record
DIN 02019906: Apo-Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800103; group id 322; item number 0718; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3195; ministry $0.3195 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019906 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14388
Interchangeable products
Co Enalapril · DIN 02291908 · $0.3195 Enalapril · DIN 02400685 · $0.3195 Enalapril · DIN 02442981 · $0.3195 Jamp-Enalapril · DIN 02474816 · $0.3195 Mar-Enalapril · DIN 02444798 · $0.3195 Mylan-Enalapril · DIN 02300060 · $0.3195 Ran-Enalapril · DIN 02352265 · $0.3195 Ratio-Enalapril · DIN 02300028 · $0.3195 Sandoz Enalapril · DIN 02299976 · $0.3195 Taro-Enalapril · DIN 02300141 · $0.3195 Teva-Enalapril · DIN 02233007 · $0.3195 Vasotec · DIN 00670928 · $0.3195
Shortage status: resolved shortage (ended 2023-12-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019906
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension, or renovascular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CAPTOPRIL · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) INDICATIONS AND CLINICAL USE Hypertension APO-CAPTO (captopril) is indicated for the treatment of essential or renovascular hypertension. PM: https://pdf.hres.ca/dpd_pm/00022606.PDF; date November 1, 2013; DIN 00893595; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph and 21 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS VASOTEC® (enalapril) is indicated for:  essential or renovascular hypertension  treatment of symptomatic congestive heart failure Hypertension VASOTEC® is indicated in the treatment of essential or renovascular hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. In using VASOTEC® consideration should be given to the risk of angioedema (see 7 WARNINGS AND PRECAUTIONS). Congestive Heart Failure VASOTEC® is indicated in the treatment of symptomatic congestive heart failure usually in combination with diuretics and/or digitalis. In these patients, VASOTEC® improves symptoms, increases survival, and decreases the frequency of hospitali zation (see 14 CLINICAL TRIALS for details and limitations of survival trials). Treatment with VASOTEC® should be initiated under close medical supervision. In clinically stable asymptomatic patients with left ventricul ar dysfunction (ejection fraction ≤35%), VASOTEC® decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see 14 CLINICAL TRIALS for details and limitations of survival trials). 1.1 Pediatrics… https://pdf.hres.ca/dpd_pm/00061923.PDF PM date: not printed or not captured Source product: VASOTEC; DIN 00670901; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. In using VASERETIC® consideration should be given to the risk of angioedema (see 7 WARNINGS AND PRECAUTIONS - General). VASERETIC® is not indicated for initial therapy. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of VASERETIC® has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00068096.PDF PM date: November 4, 2022 Source product: VASERETIC; DIN 00657298; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Co Enalapril · DIN 02291886 Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291886

Check this DIN again

Vasotec · DIN 00708879 Shortage status: active shortage (reported 2026-06-25, estimated to end 2026-10-09, last updated 2026-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00708879

Check this DIN again

Co Enalapril · DIN 02291894 Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291894

Check this DIN again